Bank of Scotland Corporate is to provide AIM-listed IS Pharma with a facility worth £8m (€10m) to fund the company’s continued growth and acquisition plans. IS Pharma is a late-stage pharmaceuticals and medical devices business in the specialist hospital medicine sector, with a current focus on critical care, neurology and oncology. The Chester-based company recently acquired Swiss pharmaceuticals group, Speciality European Pharmaceuticals, for £9.25m. IS Pharma, previously Maelor, adopted its new name following the acquisition, which has given it a new portfolio of specialist hospital pharmaceutical products.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.